Publishing prescription drug advertisements without permission Elise was fined 200,000 yuan

Image source: Shanghai Municipal Administration of Market Supervision website

Specifically, on April 10, 2021, in order to promote its drug "vomitinib mesylate tablets" (prescription drugs), Alis commissioned the Shanghai Xishan Information Consulting Service Center to hold an academic promotion meeting at the Westin Hotel in Lucheng District, Wenzhou City.

During the meeting, Ailis commissioned the Shanghai Xishan Information Consulting Service Center to place 6 roll-up treasure print advertisements in the lobby, conference check-in and venue of the above-mentioned hotel. Shanghai Pudong New Area Market Supervision and Administration Bureau said that the above-mentioned print advertisements were provided by Ailisi with specific content, and entrusted to the Shanghai Xishan Information Consulting Service Center to produce, a total of 6 productions, the production cost of 2,000 yuan. Shanghai Alis Pharmaceutical Technology Co., Ltd. is the advertiser and publisher of the above advertisement, and has not obtained the license to publish the advertisement of "vominet mesylate tablets" at the time of the incident.

The regulatory authorities said that the above-mentioned behavior of Ailis violated the relevant provisions of the Advertising Law of the People's Republic of China, ordered it to stop publishing advertisements, eliminate the impact within the corresponding scope, and fined 200,000 yuan.

It is understood that Shanghai Ailisi Pharmaceutical Technology Co., Ltd. is a company mainly engaged in the research and development of various drugs. In the secondary market, the company's stock price fell 0.31% from the previous trading day to close at 28.75 yuan / share. As of now, the total market value of the company is 12.94 billion yuan. (Zhongxin Jingwei APP)